Table 2.

Circulating levels of ANGPTL2 in cancer.

Reference	Patients	Serum ANGPTL2 (ng/ml)	ELISA kit	Conclusion of the study
[30]	Non-small-cell lung cancer, China	8.4 ± 1.7 versus 4.9 ± 1.0 in controls	USCN Life Science Inc., China	High ANGPTL2 is a novel potential biomarker for diagnosis and prognosis of patients with non-small-cell lung cancer.
[32]	Breast cancer, Japan	~4.0 versus 2.0 in controls	IBL, Japan	High ANGPTL2 in breast cancer patients could represent a potential marker of breast cancer metastasis.
[33]	Hepatocellular carcinoma, China	Values not given (ANGPTL2 not increased in cancer patients)	Not mentioned	ANGPTL2 drives hepatocellular carcinoma metastasis.
[34]	Esophageal cancer, Japan	~1.5 versus 0.8 in controls	IBL, Japan	High ANGPTL2 is a novel biomarker for diagnosis and prognosis of patients with esophageal cancer.
[40]	Colorectal cancer, Japan	~1.5 versus 0.8 in controls	IBL, Japan	ANGPTL2 is a potential marker for diagnosis, early recurrence and prognosis in colorectal cancer patients.
[38]	Colorectal cancer, Japan	1.9 (meta (+)) versus 1.5 (meta (−))	IBL, Japan	ANGPTL2 improves preoperative detection of lymph node metastasis in colorectal cancer.
[39]	Gastric cancer, Japan	~1.5 versus 0.8 in controls	IBL, Japan	High ANGPTL2 correlates with the metastatic properties of gastric cancer and could be a biomarker for early diagnosis and recurrence.
[41]	Colorectal cancer, Japan	~3.5 versus 2.7 in controls	IBL, Japan	High ANGPTL2 could be a potential biomarker for early detection of colorectal cancer.
[42]	Gastric cancer, Japan	~3.6 versus 2.7 in controls	IBL, Japan	High ANGPTL2 could be a potential biomarker for gastric cancer.